Wall Street analyst estimates for Matinas BioPharma Holdings, Inc. (MTNB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology underpins its product development efforts.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 7 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 8 |
| Avg rating (1-5) | 0.88 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-1.32 | ||
| 2026-08-13 | $-0.21 | $-1.32 | +84.1% |
| 2026-05-08 | $-0.30 | $-1.32 | +77.2% |
| 2026-03-31 | $-0.26 | $-0.78 | +66.7% |
| 2025-11-10 | $-0.40 | $-1.05 | +62.1% |
| 2025-08-14 | $-1.03 | $-1.25 | +17.6% |
| 2025-04-15 | $-1.68 | $-1.50 | -12.0% |
| 2025-04-04 | $-1.00 | $-1.50 | +33.3% |
Valuation Ratios
| Price / Book | 0.60 |
| EV / EBITDA | -0.07 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | $149687 | $119750 | $89812 | $158333 | $33000 | $3.2M | $1.1M | 0 | 0 |
| Cost of Revenue | $52644 | $9.0M | $6.8M | $11.2M | $14.4M | $14.6M | $16.7M | $941000 | $972000 | $456000 |
| Gross Profit | -$52644 | -$8.9M | -$6.7M | -$11.1M | -$14.2M | -$14.6M | -$13.5M | $155000 | -$972000 | -$456000 |
| Research & Development | $3.9M | $9.0M | $6.8M | $11.2M | $14.4M | $14.6M | $16.7M | $14.5M | $11.4M | $85000 |
| Selling, General & Admin | $4.3M | $7.6M | $8.0M | $7.8M | $10.0M | $10.2M | $11.1M | $9.4M | $7.8M | $6.9M |
| Operating Expenses | $8.3M | $16.7M | $14.8M | $7.8M | $10.0M | $10.2M | $11.1M | $23.9M | $19.2M | $6.5M |
| Operating Income | -$8.3M | -$16.5M | -$14.6M | -$18.9M | -$24.2M | -$24.7M | -$24.6M | -$23.8M | -$20.2M | -$7.0M |
| EBITDA | -$8.2M | -$16.4M | -$14.4M | -$18.6M | -$23.9M | -$23.0M | -$20.6M | -$22.0M | -$19.2M | -$9.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$7.6M | -$15.8M | -$14.6M | -$17.4M | -$22.4M | -$23.3M | -$21.0M | -$22.9M | -$24.3M | -$10.3M |
| Income Tax | 0 | -$356956 | -$506920 | 0 | 0 | 0 | 0 | 0 | -$80000 | 0 |
| Net Income | -$7.6M | -$15.5M | -$14.1M | -$17.4M | -$22.4M | -$23.3M | -$21.0M | -$22.9M | -$24.3M | -$10.3M |
| EPS | $-6.59 | $-8.56 | $-7.18 | $-5.37 | $-5.23 | $-5.04 | $-3.00 | $-5.28 | $-4.98 | $-2.00 |
| EPS (Diluted) | $-6.59 | $-8.56 | $-7.18 | $-5.37 | $-5.23 | $-5.04 | $-3.00 | $-5.28 | $-4.98 | $-2.00 |
| Shares Outstanding (Diluted) | $1.2M | $1.8M | $2.0M | $2.9M | $3.9M | $4.2M | $4.3M | $4.3M | $4.9M | $5.5M |
Price
| Price | $0.17 |
| Market Cap | $1M |
| Exchange | AMEX |
| Country | US |
Related companies: ACXP · ADIL · ADXN · BCLI · CDIO · HCWB · IBO
Explore sector: Healthcare · Biotechnology
More sections of MTNB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks